Roche on Gazyva in lupus nephritis presented at ASN/ACR 2019
Roche has hosted a live audio webcast and conference call on Tuesday, 12 November 2019.
| Agenda: | |
|---|---|
| Welcome | Karl Mahler, Head of Investor Relations |
| Roche in immunology – overview | Mark Eisner, Global Head of Product Development – Immunology, Infectious Disease & Ophthalmology |
| Phase II Nobility data - efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with Lupus Nephritis | Larry Tsai, Global Head of Rheumatology & Respiratory Development |
| Q&A |
Please register to access the replay* *Privacy notice